文献速递糖尿病

新诊断2型糖尿病短期强化胰岛素治疗后长期血糖缓解的预测因素

Predictors of Long-Term Glycemic Remission After 2-Week Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

本研究对124例未用药新诊断2型糖尿病患者进行2周持续皮下胰岛素输注(CSII),并用钳夹试验评估胰岛素敏感性与β细胞功能。随访2年发现血糖缓解率12个月为47.6%、24个月为30.7%,诊断年龄较轻、基线胰岛素敏感性较高及治疗后血糖较低者更易获得长期缓解。

要点

  • 2周CSII可恢复第一时相胰岛素分泌并显著改善胰岛素敏感性(P<0.0001)。
  • 12个月和24个月血糖缓解率分别为47.6%和30.7%。
  • 诊断年龄较轻、基线胰岛素敏感性较高、治疗后血糖较低者缓解机会更大。

核心结论

  • 诊断时年龄较轻、基线胰岛素敏感性较高及胰岛素治疗后血糖较低显著有利于2年血糖缓解。
  • 长期缓解归因于短期强化胰岛素治疗后胰岛素敏感性改善和β细胞功能增强。

研究设计与样本

  • 对124例未用药新诊断2型糖尿病患者进行2周CSII治疗并计划随访2年。
  • 治疗前后行正常血糖-高胰岛素钳夹试验和静脉葡萄糖耐量试验评估胰岛素敏感性(GIR)和急性胰岛素反应(AIR)。

主要发现

  • 2周CSII后第一时相胰岛素分泌恢复,GIR显著改善(P<0.0001)。
  • 随访12个月和24个月的血糖缓解率分别为47.6%和30.7%。
  • Cox分析显示CSII后血糖较高(HR 1.38;95%CI 1.15-1.66;P=0.0005)和诊断年龄较大(HR 1.34;95%CI 1.05-1.72;P=0.02)增加高血糖复发风险。
  • CSII后AIR每增加1个标准差(HR 0.75;95%CI 0.57-0.99;P=0.04)、CSII后GIR(HR 0.67;95%CI 0.48-0.93;P=0.016)及基线GIR(HR 0.71;95%CI 0.51-0.99;P=0.047)与复发风险呈负相关。

临床怎么用

  • 对新诊断2型糖尿病患者可考虑2周CSII强化治疗以改善β细胞功能和胰岛素敏感性。
  • 诊断年龄较轻、基线胰岛素敏感性较高及治疗后血糖较低者更可能获得长期血糖缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Although several studies suggest that improved β-cell function is a key determinant of glycemic remission in type 2 diabetes, other predictors remain unclear. OBJECTIVE: The aim of this clamp-based study was to identify predictors of 2-year glycemic remission after short-term intensive insulin treatment. DESIGN: A 2-year follow-up was planned in 124 drug-naive patients with type 2 diabetes who received continuous subcutaneous insulin infusion (CSII) for 2 weeks. Euglycemic-hyperinsulinemic clamps and IV glucose tolerance tests were performed to assess the insulin sensitivity [glucose infusion rate (GIR)] and acute insulin response (AIR) before and after CSII. RESULTS: First-phase insulin secretion was restored, and the GIR was significantly improved (P < 0.0001) after the 2-week CSII. Glycemic remission rates were 47.6% and 30.7% after 12 and 24 months of follow-up, respectively. Cox analysis revealed that a higher post-CSII glucose level [hazard ratio (HR), 1.38; 95% CI, 1.15 to 1.66; P = 0.0005] and older age at diabetes diagnosis (HR, 1.34; 95% CI, 1.05 to 1.72; P = 0.02) accounted for an increased risk of hyperglycemic relapse. A 1 SD increase in the AIR (HR, 0.75; 95% CI, 0.57 to 0.99; P = 0.04), GIR (HR, 0.67; 95% CI, 0.48 to 0.93; P = 0.016) after CSII, and baseline GIR (HR, 0.71; 95% CI, 0.51 to 0.99; P = 0.047) was inversely associated with this risk. CONCLUSIONS: Younger age at diabetes diagnosis, higher baseline insulin sensitivity, and lower glucose levels after insulin treatment significantly favored a 2-year glycemic remission. This long-term remission was attributed to both improved insulin sensitivity and enhanced β-cell function after short-term intensive insulin treatment.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wang H, Kuang J, Xu M, et al. Predictors of Long-Term Glycemic Remission After 2-Week Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes. J Clin Endocrinol Metab. 2019. PMID: 30629195. doi:10.1210/jc.2018-01468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。